Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platinum + etoposide + anlotinib
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Platinum + etoposide + anlotinib is a combination regimen used primarily as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC). The regimen consists of a platinum-based chemotherapy agent (cisplatin or carboplatin), the topoisomerase II inhibitor etoposide, and anlotinib, which is a novel oral multi-targeted tyrosine kinase inhibitor. Anlotinib inhibits angiogenesis by targeting multiple receptors including vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial growth factor receptor 3 (VEGFR3), fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2), fibroblast growth factor receptor 3 (FGFR3), fibroblast growth factor receptor 4 (FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), platelet-derived growth factor receptor beta (PDGFRβ), c-kit, and Ret. This combination has demonstrated improved progression-free survival and overall response rates compared to traditional chemotherapy alone in clinical studies for ES-SCLC. Anlotinib’s antiangiogenic activity provides synergistic effects with cytotoxic agents, while its toxicity profile allows for tolerable combination use[1][2][6][3].
- Brand names
- none
- Other names
- none
02
Targets
FGFR (FGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on platinum + etoposide + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platinum + etoposide + anlotinib.